Skip to content


Nubeqa (darolutamide) is a small molecule pharmaceutical. Darolutamide was first approved as Nubeqa on 2019-07-30. It has been approved in Europe to treat castration-resistant prostatic neoplasms. The pharmaceutical is active against androgen receptor. Nubeqa's patent is valid until 2036-01-28 (FDA).
Trade Name Nubeqa
Common Name Darolutamide
Indication castration-resistant prostatic neoplasms
Drug Class Non-steroid antiandrogens
Get full access now